



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

Our Reference: BL 125582/0


CSL Behring Recombinant Facility AG
Attention: Mr. Kevin D White
July 23, 2015
Sent by email


Dear Mr. White:

We are reviewing your December 5, 2014 biologics license application (BLA) for Coagulation Factor IX (Recombinant), Albumin Fusion Protein. We determined that the following information is necessary to continue our review:

1. (b) (4) [REDACTED]
2. (b) (4) [REDACTED]
3. Please provide (b) (4) [REDACTED] comparing the (b) (4) [REDACTED] and Marburg samples using the same set of (b) (4) [REDACTED] conditions. Please also provide these (b) (4) [REDACTED] on full page 8.5" x 11" scale in landscape format. This method should provide a reference to establish batch to batch consistency for the albumin moiety of the rIX-FP (b) (4) [REDACTED].
4. (b) (4) [REDACTED]

(b) (4)



5. The data presented in REP-10016 is confusing. There are clear qualitative differences in the (b) (4) of the Marburg reference sample (Lot (b) (4) reference material (Lot (b) (4) and the (b) (4) standard. These differences are not explained. The method was not validated. There are no measurements of precision, robustness specificity, or reproducibility. The sponsor should establish acceptance criteria and associated measures of percent error, or analysis of variance for all of the reported values, (b) (4). There is therefore no meaningful way to interpret this data. This method should be properly validated according to ICH Q2B. One reference that may be used for establishing measurements of precision for (b) (4)
- 

The review of this submission is on-going and issues may be added, expanded upon, or modified as we continue to review this submission.

Please submit your response to this information request as an amendment to this file by July 31, 2015 referencing the date of this request. If you anticipate you will not be able to respond by this date, please contact the Agency immediately so a new response date can be identified.

If we determine that your response to this information request constitutes a major amendment, we will notify you in writing.

The action due date for this file is December 5, 2015.

Please send an acknowledgement for receipt of this request.

If you have any questions, please contact me at (240) 402-8443.

Sincerely,

Edward Thompson
Regulatory Project Manager
FDA/CBER/OBRR/RPMS

THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW
If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify us by telephone and return it to us at the above address by mail.
Thank you